As of 2024-12-12, the EV/EBITDA ratio of BridgeBio Pharma Inc (BBIO) is -13.26. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. BridgeBio's latest enterprise value is 6,941.26 mil USD. BridgeBio's TTM EBITDA according to its financial statements is -523.38 mil USD. Dividing these 2 quantities gives us the above BridgeBio EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.2x - 16.0x | 15.6x |
| Forward P/E multiples | 15.7x - 25.3x | 18.6x |
| Fair Price | (51.11) - (51.94) | (55.11) |
| Upside | -276.0% - -278.9% | -289.8% |
| Date | EV/EBITDA |
| 2024-11-29 | -12.56 |
| 2024-11-27 | -12.70 |
| 2024-11-26 | -12.32 |
| 2024-11-25 | -12.59 |
| 2024-11-22 | -11.23 |
| 2024-11-21 | -11.17 |
| 2024-11-20 | -11.10 |
| 2024-11-19 | -10.92 |
| 2024-11-18 | -10.85 |
| 2024-11-15 | -11.34 |
| 2024-11-14 | -11.48 |
| 2024-11-13 | -11.73 |
| 2024-11-12 | -11.67 |
| 2024-11-11 | -12.21 |
| 2024-11-08 | -12.56 |
| 2024-11-07 | -12.12 |
| 2024-11-06 | -12.02 |
| 2024-11-05 | -11.99 |
| 2024-11-04 | -11.88 |
| 2024-11-01 | -11.98 |
| 2024-10-31 | -11.23 |
| 2024-10-30 | -11.37 |
| 2024-10-29 | -11.62 |
| 2024-10-28 | -11.60 |
| 2024-10-25 | -11.38 |
| 2024-10-24 | -11.50 |
| 2024-10-23 | -11.61 |
| 2024-10-22 | -11.78 |
| 2024-10-21 | -11.86 |
| 2024-10-18 | -12.17 |
| 2024-10-17 | -12.23 |
| 2024-10-16 | -12.29 |
| 2024-10-15 | -11.94 |
| 2024-10-14 | -12.09 |
| 2024-10-11 | -12.13 |
| 2024-10-10 | -11.79 |
| 2024-10-09 | -11.22 |
| 2024-10-08 | -11.71 |
| 2024-10-07 | -11.75 |
| 2024-10-04 | -11.89 |
| 2024-10-03 | -12.03 |
| 2024-10-02 | -11.83 |
| 2024-10-01 | -11.73 |
| 2024-09-30 | -11.97 |
| 2024-09-27 | -11.78 |
| 2024-09-26 | -11.62 |
| 2024-09-25 | -11.63 |
| 2024-09-24 | -11.75 |
| 2024-09-23 | -11.95 |
| 2024-09-20 | -12.43 |